PEPTIDEREPORT

Video claim watch

New Data Released on Weight-Loss Drug Retatrutide

A large morning-news audience received a compressed explanation of new retatrutide data, making it useful for tracking public interpretation of trial results.

Good Morning America channel2:55 runtime51K views when checked

Published May 21, 2026. Metadata checked Jul 12, 2026.

Watch on YouTube

Transcript review

6 material claims logged

Published with source gaps audit stateauto-captioned transcript0 operational-guidance flags1 source gap

Reviewed Jul 12, 2026. Next review Aug 12, 2026.

timely trial-results summary, but it relies on sponsor topline data and overstates product identity.

auto-caption available; no chapters.

Claim-by-claim audit

What the video says, and what needs checking

00:02:22
High-risk regulatory claim

projects an FDA-submission/approval timeframe.

Review topic: regulatory forecast.

Checked against: Primary-source record still needed

Lilly filings and FDA status; forecasts are not decisions.

00:02:40
High-risk quality claimHigh-risk regulatory claim

says anything advertised now “is not the real drug.”

Review topic: product identity.

Checked against: FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.

warning letters. Better wording: no consumer product is FDA-approved or Lilly-supplied; chemical identity of a specific sample requires testing.

Connected research

Compounds discussed

Retatrutide Retatrutide has produced large weight reductions in randomized Phase 2 and Phase 3 trials, but it remains unapproved. Long-term outcomes, direct comparisons, rare risks, durability, and final regulatory decisions remain unresolved. Tirzepatide Tirzepatide is a dual GIP and GLP-1 receptor agonist sold as Mounjaro and Zepbound for specific FDA-approved indications. Randomized trials support diabetes and chronic weight-management uses. Public discussion should remain separate from label language and trial populations. Semaglutide Semaglutide is a GLP-1 receptor agonist sold as Ozempic, Wegovy, and Rybelsus for specific FDA-approved indications. Randomized trials support diabetes and chronic weight-management uses. Off-label, compounded, and broader behavioral claims require separate evidence and regulatory review.

Source check

Records used in this claim audit

Retatrutide for Obesity: A Phase 2 Trial

New England Journal of Medicine · Peer reviewed · Jun 26, 2023 · accessed Jul 1, 2026

Retatrutide phase 2 obesity trial (NEJM 2023): at 12 mg, mean body weight fell 17.5% at week 24 and 24.2% at week 48; GI adverse events were most common.

12 linked pagesOpen original · nejm-retatrutide-phase2-2023